Results 251 to 260 of about 18,936 (283)

Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus

Nguyen VD, Bright M, Zhou Y, Morgan BP, Zelek WM.   +4 more
europepmc   +1 more source

Gene variant C3 glomerulonephritis with chronic urinary tract infection: A case report and literature review. [PDF]

Medicine (Baltimore)
Xu C, Fan J.
europepmc   +1 more source

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword. [PDF]

Front Immunol
Yang R, Fu D, Liao A.
europepmc   +1 more source

Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review. [PDF]

BMC Nephrol
Musalem P.
europepmc   +1 more source

Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer. [PDF]

BMC Gastroenterol
Qi TT, Zhou SJ, Yu Z, Li Y, Chen JQ.
europepmc   +1 more source

Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice. [PDF]

Mol Ther
Li C, Georgakopoulou A, Paschoudi K, Anderson AK, Huang L, Gil S, Giannaki M, Vlachaki E, Newby GA, Liu DR, Yannaki E, Kiem HP, Lieber A.   +12 more
europepmc   +1 more source

Beyond the Initial Episode, Recurrent Hemolytic Uremic Syndrome Unveiled. [PDF]

Indian J Nephrol
Abhinay A, Vijayakumar V, Kumar N, Panda S.   +3 more
europepmc   +1 more source

Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment. [PDF]

Commun Biol
Kato Y, Rice N, Pokrass M, Jeong J, Rodriguez R, Field JJ, Nowyhed H.   +6 more
europepmc   +1 more source

Dynamics of the CD9 interactome during bacterial infection of epithelial cells by proximity labelling proteomics

Wolverson P, Fernandes Parreira I, Collins M, Shaw J, Green L.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology, 2022
3001 Background: FOR46, a fully human antibody (ab) conjugated to monomethyl auristatin E (MMAE), targets a tumor selective epitope of CD46, which is highly expressed in mCRPC and treatment-emergent small cell neuroendocrine cancer (t-SCNC).
R. Aggarwal, J. Vuky, David J. VanderWeele, M. Rettig, E. Heath, T. Beer, Jiaoti Huang, Nela Pawłowska, R. Sinit, Jill Abbey, Bin Liu, M. Nasoff, A. Dorr, E. Small   +13 more
semanticscholar   +1 more source